Teva R&D chief Eric Hughes steps down
TEVA•Teva R&D chief Eric Hughes will leave for a role outside the company, while David Gardiner leads the transition and Teva begins searching for a permanent successor.
1. Leadership transition
Eric Hughes, Teva’s executive vice president of global R&D and chief medical officer, will leave for a role outside the company and remain for the coming months to support the transition. David Gardiner, head of innovative medicines and clinical development, becomes R&D transition lead immediately, reporting to CEO Richard Francis. Teva is beginning a search for a permanent successor.




